Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (605016) — Net Asset Quality Index
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (605016) has a Net Asset Quality Index of 74.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.80 Billion minus total liabilities of CN¥717.55 Million yields net assets of CN¥2.08 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check financial resilience of Shandong Bailong Chuangyuan Bio-Tech Co. to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Net Asset Quality Index Over Time (2016–2025)
This chart shows how Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s Net Asset Quality Index has evolved across 10 annual periods from 2016 to 2025. As of March 2026, the index stands at 74.4%, representing net assets of CN¥2.08 Billion against total assets of CN¥2.80 Billion CNY. See how liquid is Shandong Bailong Chuangyuan Bio-Tech Co.'s working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (2016–2025)
The table below presents the year-by-year Net Asset Quality Index for Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. from 2016 to 2025, covering 10 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 605016 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 80.5% | CN¥1.96 Billion | CN¥2.44 Billion | CN¥475.19 Million | ▼ -2.9 pp |
| 2024 | 83.4% | CN¥1.68 Billion | CN¥2.01 Billion | CN¥334.27 Million | ▼ -2.6 pp |
| 2023 | 86.0% | CN¥1.51 Billion | CN¥1.75 Billion | CN¥246.35 Million | ▼ -5.4 pp |
| 2022 | 91.4% | CN¥1.34 Billion | CN¥1.47 Billion | CN¥126.99 Million | ▼ -2.5 pp |
| 2021 | 93.8% | CN¥1.20 Billion | CN¥1.28 Billion | CN¥79.05 Million | ▲ +11.2 pp |
| 2020 | 82.7% | CN¥691.09 Million | CN¥836.00 Million | CN¥144.91 Million | ▲ +3.5 pp |
| 2019 | 79.2% | CN¥597.07 Million | CN¥754.35 Million | CN¥157.28 Million | ▼ -3.1 pp |
| 2018 | 82.3% | CN¥501.71 Million | CN¥609.80 Million | CN¥108.09 Million | ▲ +12.5 pp |
| 2017 | 69.7% | CN¥436.41 Million | CN¥625.78 Million | CN¥189.38 Million | ▲ +12.3 pp |
| 2016 | 57.4% | CN¥362.67 Million | CN¥631.82 Million | CN¥269.14 Million | — |